Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,213,198 papers from all fields of science
Search
Sign In
Create Free Account
Felbamate:MCnc:Pt:Ser/Plas:Qn
Known as:
Felbamate:MCnc:Pt:Sor/Plas:Qn
, Felbamat:KütlKons:Zml?:Ser/Plaz:Kant
, felbamato:concentración de masa:punto en el tiempo:suero/plasma:cuantitativo:
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Plas
Serum
Unit of Mass Concentration
felbamate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Behavioural, immune and humoral antidepressant-like effects ofantiepileptic felbamate in rodent models
A. Šulcová
,
J. Pistovčáková
,
A. Makatsori
,
D. Jezova
2006
Corpus ID: 151732882
Antiepilectic drug of the 3rd generation felbamate produced in two rodent models of depression antidepressant-like effects on…
Expand
2005
2005
Acute Felbamate Overdose with Crystalluria
K. Meier
,
K. Olson
,
J. Olson
Clinical toxicology
2005
Corpus ID: 43087508
A 3-year-old child developed vomiting, ataxia, and crystalluria after ingestion of approximately 232 mg/kg of felbamate elixir…
Expand
2001
2001
Brief Communication : Felbamate Urolithiasis
S. Sparagana
,
W. Strand
,
R. Adams
2001
Corpus ID: 69083727
Review
1998
Review
1998
AN OVERVIEW OF THE NEW ANTIEPILEPTIC DRUGS
R. Mattson
1998
Corpus ID: 71182057
BACKGROUND- Within the past several years, a number of new antiepileptic drugs (AEDs) have become available for use in the United…
Expand
1997
1997
Il felbamato negli spasmi infantili farmacoresistenti
G. Coppola
,
A. Nazzaro
,
A. Pascotto
1997
Corpus ID: 187259906
1997
1997
Il felbamato in add-on nel trattamento delle epilessie sintomatiche farmacoresistenti
M. Bottitta
,
S. A. Musumeci
,
+4 authors
M. Elia
1997
Corpus ID: 79002097
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE